Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Conditions
Interventions
ABBV-CLS-628
Placebo
Locations
75
United States
National Institute of Clinical Research - Garden Grove /ID# 271418
Garden Grove, California, United States
Valiance Clinical Research - Huntington Park /ID# 270634
Huntington Park, California, United States
Academic Medical Research Institute - Los Angeles /ID# 270502
Los Angeles, California, United States
UC Irvine Medical Center /ID# 270811
Orange, California, United States
University Of California, San Francisco /ID# 270326
San Francisco, California, United States
Yale University School of Medicine /ID# 270675
New Haven, Connecticut, United States
Start Date
June 9, 2025
Primary Completion Date
August 1, 2029
Completion Date
August 1, 2029
Last Updated
February 4, 2026
NCT04939935
NCT07454174
NCT07260071
NCT06065852
NCT03901521
NCT06594367
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions